Management of hypertriglyceridemia for prevention of atherosclerotic cardiovascular disease.
Mendelian randomization data strongly suggest that hypertriglyceridemia (HTG) causes atherosclerotic cardiovascular disease (ASCVD), and so triglyceride (TG) level-lowering treatment in HTG is now more strongly recommended to address the residual ASCVD risk than has been the case in (generally earlier) published guidelines. Fibrates are the best-established agents for TG level lowering and are generally used as first-line treatment of TG levels greater than 500 mg/dL. Statins are the best-established agents for ASCVD prevention, and so are usually used as first-line treatment of TG levels less than 500 mg/dL.
Atherometabolic Research, Utah Foundation for Biomedical Research, 419 Wakara Way, Suite 211, Salt Lake City, UT 84108, USA. Electronic address: eliot.brinton@utah.edu.
Eliot A
EA
Brinton
D050197:Atherosclerosis / Q000097:blood / Q000209:etiology / Q000517:prevention & control; D019468:Disease Management; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D015228:Hypertriglyceridemia / Q000097:blood / Q000150:complications / Q000188:drug therapy; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D014280:Triglycerides / Q000097:blood*
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D014280:Triglycerides
Atherosclerosis; Cardiovascular disease; Hypertriglyceridemia; Triglycerides